News

The Centers for Disease Control and Prevention (CDC) is preparing for staff cuts and the Trump Administration may be withholding public health information in one of the agency's publications, which can impact disclosing health information being seen by providers and other stakeholders.

Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.

Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.

This week, a study on children with invasive candidiasis showed that switching treatment was just as effective, AI is being explored as a tool to combat AMR, and more.

There are concerns around norovirus risks associated with a certain harvest from Louisiana.

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

Kirsten Nielsen, PhD, discusses how her team’s research could lead to better understanding and treatment of cryptococcal meningitis.

The association’s Executive Director Georges Benjamin, MD, offers some commentary as to why they have concerns around him as Health and Human Services Secretary.

Researchers identify Camp Hill virus, a novel henipavirus in shrews, raising concerns about human exposure to emerging infectious diseases.

Robert Walker, MD discussed the company's application for full licensure and the importance of vaccination.

In a randomized control study, the antiviral demonstrated reduced risk and could potentially influence treatment management for patients with a moderate or high viral load.

Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.

SARS-CoV-2 infection was associated with rapid growth of plaque in the coronary arteries and an increased risk of cardiovascular events compared to noninfected patients.

The latest Phase 2/3 trial results show NVX-CoV2601 outperforms its predecessor, offering protection against emerging COVID-19 strains.

The successful implementation of AI into trying to combat resistance will require broader integration efforts, training, and regulatory frameworks.

European agencies warn that non-medical fungicide use may be fueling resistance in A fumigatus, a mold responsible for severe human infections.

The agency pointed out that pathogens such as Klebsiella pneumoniae and Escherichia coli (E coli) are problematic for healthcare systems and the general public across Europe.

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Levofloxacin was associated with statistically significant reduction in tuberculosis developing in household contacts of persons with multidrug- resistant TB in a meta-analysis, but not in the constituent controlled trials.

Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.

Children with invasive candidiasis had successful outcome whether IV antifungal treatment was completed or converted to enteral to reduce risk of infusion site infections and costs.

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

Prashant Kumar’s study on indoor air quality aboard cruise ships highlights the critical role of ventilation and masking in reducing infection risks.

Cabotegravir (Vocabria) + rilpivirine (Rekambys) is the first and only complete long-acting injectable regimen for the treatment of HIV.

Kansas is experiencing the largest tuberculosis outbreak in decades, a preview into vaccines and treatments up for FDA approval this winter/spring, and more.

The company said its oral therapy, S-337395, achieved a 88.94% reduction in viral load.

Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.

This is the second in a series looking at the intersection of government and public health. In this segment, Contagion Editor-in-Chief Jason Gallagher, FCCP, FIDP, FIDSA, BCPS, discusses the WHO pullout, and the pauses on federal communication and research grants.